

# *Cancer Incidence in Connecticut, 2006*

*December, 2008*

## **Technical Notes**

This report includes data on “invasive” (“malignant”) cancers diagnosed in 2006 among male and female residents of Connecticut , as reported to the Connecticut Tumor Registry (CTR). The CTR is funded by the National Cancer Institute (NCI), as part of the Surveillance, Epidemiology and End Results (SEER) Program of high-quality population-based cancer registries.

This report shows “age-specific” incidence rates for males and females. These rates represent the number of cancers diagnosed in a specific age group divided by the estimated number of persons in the Connecticut population (see Appendix) who are in that age category, expressed as a rate per 100,000 population. “Crude” incidence rates are also shown, which represent the total number of cancers (for all age groups combined) divided by the estimated total Connecticut population of males or females in 2006, and are expressed as a rate per 100,000.

In making comparisons of cancer incidence by time period and geographic area, rates are often "age adjusted" (“age standardized”) to take into account changes in the age structure of the population. The "aging" of the population, or the growing numbers of elderly persons, results in increases in total cancer rates because these rates rise with age. For many years, the Connecticut Tumor Registry and the SEER Program calculated age-standardized cancer incidence rates by using the age distribution of the entire U.S. population (males and females combined) in 1970 as the standard. Recently, age-standardized rates have been calculated using the 2000 standard population. Age-

standardized incidence rates using both the 1970 and the 2000 standard population are provided in this report. Age-standardized incidence rates are fictitious rates, obtained by applying the actual age-specific rates in Connecticut to the age distribution of the total U.S. U.S. population (in 1970 or 2000). Age-standardized rates are used solely for making comparisons by time period or geographic area.

The numbers and rates in this monograph were obtained from a data file that was prepared in November, 2008 and submitted by the Registry to NCI, which will be used by NCI in preparing statistical information. Cancer incidence rates that appear in the present report will differ slightly from those published by SEER/NCI, because the present report classifies cancers into various types that are consistent with previous reports from the Registry. The Registry's system of classifying cancers by groups of "sites" or "types" differs slightly from that used in SEER/NCI publications (see [www.seer.cancer.gov](http://www.seer.cancer.gov)). The present report includes cancers ascertained only from death certificates ("death certificate only" or "DCO"), although the date of cancer diagnosis is unknown; DCOs comprise only about 1% of all cancers.

The data in this report will be updated in the future, to include delayed reports received by the Registry after the time that this report was prepared. NCI provides data with statistical adjustment for delayed reports from SEER registries; the methods are described on the SEER website ([www.seer.cancer.gov](http://www.seer.cancer.gov)).

The present report includes data for two additional categories of cancers that were not included in previous monographs (until last year) and which became "reportable" to registries in the SEER Program starting with year of diagnosis 2001; these categories are

“myeloproliferative disorders” (including polycythemia vera) and “myelodysplastic syndromes” (including certain “refractory” anemias). The specific codes used by the SEER Program for these two types of cancers are provided in the Appendix to this report.

Data in this report are for invasive (malignant) cancers. Because of the difficulty in distinguishing “in situ” (pre-invasive) from invasive bladder cancers, however, bladder cancers reported as “in situ” have been recoded to invasive in reports from the CTR and NCI. “In situ” refers cancers have not penetrated (microscopically) into deeper layers of the tissue in which the cancer originated, and therefore have little chance of spreading to other tissues or organs and (therefore) little chance of increasing the risk of death from . cancer.

MALES

**Numbers of Invasive Cancers and Age-Specific Incidence Rates (per 100,000)  
Males, 2006: Age at Diagnosis 0-4 Years through 15-19 Years**

Site/type	Age 0-4		Age 5-9		Age 10-14		Age 15-19	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate
All invasive	24	23.13	17	15.01	20	16.19	33	25.82
Lymphoma								
Hodgkin	0	.00	1	.88	1	.81	6	4.69
Non-Hodgkin	1	.96	4	3.53	4	3.24	4	3.13
Oral cavity, pharynx	0	.00	0	.00	0	.00	1	.78
Esophagus	0	.00	0	.00	0	.00	0	.00
Stomach	0	.00	0	.00	0	.00	0	.00
Colon	0	.00	0	.00	0	.00	0	.00
Rectum	0	.00	0	.00	0	.00	0	.00
Liver	0	.00	0	.00	0	.00	1	.78
Gallbladder	0	.00	0	.00	0	.00	0	.00
Pancreas	0	.00	0	.00	0	.00	0	.00
Larynx	0	.00	0	.00	0	.00	0	.00
Lung	0	.00	0	.00	0	.00	0	.00
Connective tissue	2	1.93	2	1.77	1	.81	1	.78
Melanoma, skin	0	.00	1	.88	2	1.62	0	.00
Prostate	0	.00	0	.00	0	.00	0	.00
Testis	0	.00	1	.87	0	.00	3	2.35
Bladder	0	.00	0	.00	0	.00	0	.00
Kidney	4	3.85	0	.00	0	.00	0	.00
Brain, CNS	2	1.93	0	.00	4	3.24	3	2.35
Thyroid	0	.00	0	.00	1	.81	3	2.35
Multiple myeloma	0	.00	0	.00	0	.00	0	.00
Leukemia	8	7.71	4	3.53	4	3.24	2	1.56
Kaposi sarcoma	0	.00	0	.00	0	.00	0	.00
Unknown site	0	.00	0	.00	0	.00	0	.00
Chronic myelopro- Liferative	0	.00	0	.00	0	.00	0	.00
Myelodysplastic	0	.00	1	.88	0	.00	1	.78

CNS: Central Nervous System (see Appendix for codes).

All rates are per 100,000 (males) in the estimated population of Connecticut in 2006. Not all specific types/sites are shown separately, so that the sum of the numbers for all of the sites/types shown is less than the number for all invasive cancers combined. See Appendix for a list of the codes used for the sites or types shown.

Numbers of Cancers, and Incidence Rates (per 100,000)

**Males, 2006: Age at Diagnosis 20-24 Years through 35-39 Years**

Site/type	Age 20-24		Age 25-29		Age 30-34		Age 35-39	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate
All invasive	38	33.29	54	53.64	59	56.37	120	95.22
Lymphoma								
Hodgkin	6	5.26	2	1.99	8	7.64	5	3.97
Non-Hodgkin	3	2.63	3	2.98	3	2.87	10	7.93
Oral cavity,								
pharynx	0	.00	0	.00	3	2.87	5	3.97
Esophagus	0	.00	0	.00	0	.00	1	.79
Stomach	0	.00	1	.99	0	.00	3	2.38
Colon	3	2.63	3	2.98	2	1.91	9	7.14
Rectum	0	.00	0	.00	1	.96	4	3.17
Liver	0	.00	0	.00	0	.00	0	.00
Gallbladder	0	.00	1	.99	0	.00	0	.00
Pancreas	0	.00	0	.00	1	.96	1	.79
Larynx	0	.00	0	.00	0	.00	0	.00
Lung	0	.00	0	.00	3	2.87	1	.79
Connective tissue	0	.00	3	2.98	1	.96	3	2.38
Melanoma, skin	6	5.26	5	4.97	9	8.60	16	12.70
Prostate	0	.00	0	.00	0	.00	0	.00
Testis	8	7.01	16	15.89	11	10.51	25	19.84
Bladder	0	.00	2	1.99	0	.00	4	3.17
Kidney	0	.00	0	.00	4	3.82	6	4.76
Brain CNS	1	.88	7	6.95	3	2.87	5	3.97
Thyroid	2	1.75	8	7.95	5	4.78	9	7.14
Multiple myeloma	0	.00	0	.00	0	.00	1	.79
Leukemia	4	3.50	1	.99	2	1.91	4	3.17
Kaposi sarcoma	0	.00	0	.00	0	.00	1	.79
Unknown site	1	.88	0	.00	0	.00	2	1.59
Chronic myelo- proliferative	0	.00	1	.99	1	.96	1	.79
Myelodysplastic	0	.00	0	.00	0	.00	0	.00

**Numbers of Cancers, and Incidence Rates (per 100,000)**

**Males, 2006: Age at Diagnosis 40-44 Years through 55-59 Years**

Site/type	Age 40-44		Age 45-49		Age 50-54		Age 55-59	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate
All invasive	240	168.87	415	289.37	758	603.28	1118	1040.14
Lymphoma								
Hodgkin	6	4.22	5	3.49	5	3.98	0	.00
Non-Hodgkin	20	14.07	22	15.34	41	32.63	39	36.28
Oral cavity,								
pharynx	11	7.74	28	19.52	43	34.22	50	46.52
Esophagus	3	2.11	3	2.09	6	4.78	20	18.61
Stomach	7	4.93	9	6.28	19	15.12	21	19.54
Colon	16	11.26	22	15.34	45	35.81	45	41.87
Rectum	12	8.44	18	12.55	30	23.88	33	30.70
Liver	3	2.11	7	4.88	29	23.08	27	25.12
Gallbladder	1	.70	1	.70	2	1.59	2	1.86
Pancreas	2	1.41	15	10.46	20	15.92	22	20.47
Larynx	1	.70	6	4.18	8	6.37	13	12.09
Lung	11	7.74	35	24.40	81	64.47	120	111.64
Connective tissue	8	5.63	5	3.49	6	4.78	11	10.23
Melanoma, skin	29	20.41	48	33.47	41	32.63	67	62.33
Prostate	12	8.44	67	46.72	209	166.34	435	404.70
Testis	12	8.44	11	7.67	6	4.78	3	2.79
Bladder	12	8.44	12	8.37	31	24.67	64	59.54
Kidney	17	11.96	34	23.71	41	32.63	42	39.07
Brain, CNS	11	7.74	11	7.67	14	11.14	21	19.54
Thyroid	13	9.15	6	4.18	18	14.33	16	14.89
Multiple myeloma	2	1.41	4	2.79	7	5.57	5	4.65
Leukemia	13	9.15	10	6.97	14	11.14	19	17.68
Kaposi sarcoma	2	1.41	3	2.09	3	2.39	0	.00
Unknown site	1	.70	10	6.97	9	7.16	13	12.09
Chronic myelo-								
Proliferative	1	.70	4	2.79	8	6.37	8	7.44
Myelodysplastic	0	.00	3	2.09	1	.80	4	3.72

Numbers of Cancers, and Incidence Rates (per 100,000)

**Males, 2006 Age at Diagnosis 60-64 through 75-79 Years**

Site/type	Age 60-64		Age 65-69		Age 70-74		Age 75-79	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate
All invasive	1242	1556.74	1270	2225.63	1358	2971.94	1416	3577.20
Lymphoma								
Hodgkin	4	5.01	4	7.01	2	4.38	3	7.58
Non-Hodgkin	32	40.11	29	50.82	57	124.74	60	151.58
Oral cavity,								
pharynx	46	57.66	30	52.57	29	63.47	18	45.47
Esophagus	28	35.10	22	38.55	23	50.33	15	37.89
Stomach	24	30.08	20	35.05	27	59.09	29	73.26
Colon	63	78.97	80	140.19	89	194.77	110	277.89
Rectum	32	40.11	38	66.59	42	91.92	36	90.95
Liver	22	27.58	14	24.53	22	48.15	19	48.00
Gallbladder	5	6.27	10	17.52	8	17.51	12	30.32
Pancreas	32	40.11	31	54.32	41	89.73	34	85.89
Larynx	20	25.07	15	26.29	12	26.26	13	32.84
Lung	147	184.25	185	324.19	208	455.20	231	583.57
Connective tissue	4	5.01	3	5.26	6	13.13	11	27.79
Melanoma, skin	65	81.47	52	91.12	57	124.74	62	156.63
Prostate	515	645.51	516	904.23	457	1000.13	389	982.72
Testis	2	2.51	0	.00	1	2.19	0	.00
Bladder	74	92.75	77	134.93	119	260.43	141	356.20
Kidney	44	55.15	38	66.59	37	80.97	58	146.52
Brain, CNS	8	10.03	10	17.52	6	13.13	11	27.79
Thyroid	13	16.29	10	17.52	7	15.32	9	22.74
Multiple myeloma	6	7.52	17	29.79	15	32.83	21	53.05
Leukemia	16	20.05	22	38.55	19	41.58	35	88.42
Kaposi sarcoma	1	1.25	0	.00	0	.00	0	.00
Unknown site	11	13.79	15	26.29	28	61.28	32	80.84
Chronic myelo- proliferative	1	1.25	2	3.50	3	6.57	9	22.74
Myelodysplastic	6	7.52	5	8.76	11	24.07	23	58.10



Numbers of Cancers, and Incidence Rates (per 100,000)

**Males, 2006 Age at Diagnosis 80-84 through 85+ Years**

Site/type	Age 80-84		Age 85+	
	Number	Rate	Number	Rate
All invasive	996	3542.72	735	3143.98
-----				
Lymphoma				
Hodgkin	7	24.90	1	4.28
Non-Hodgkin	36	128.05	42	179.66
Oral cavity, pharynx	21	74.70	10	42.78
Esophagus	21	74.70	6	25.67
Stomach	28	99.59	25	106.94
Colon	84	298.78	75	320.81
Rectum	21	74.70	20	85.55
Liver	14	49.80	14	59.89
Gallbladder	6	21.34	7	29.94
Pancreas	36	128.05	21	89.83
Larynx	14	49.80	8	34.22
Lung	174	618.91	107	457.70
Connective tissue	4	14.23	5	21.39
Melanoma, skin	58	206.30	23	98.38
Prostate	204	725.62	140	598.85
Testis	0	.00	0	.00
Bladder	117	416.16	87	372.14
Kidney	23	81.81	21	89.83
Brain, CNS	8	28.46	3	12.83
Thyroid	2	7.11	2	8.56
Multiple myeloma	14	49.80	11	47.05
Leukemia	31	110.27	32	136.88
Kaposi sarcoma	0	.00	3	12.83
Unknown site	25	88.92	24	102.66
Chronic myeloprolif.	2	7.11	3	12.83
Myelodysplastic	19	67.58	24	102.66

Numbers of Cancers, and Incidence Rates (per 100,000)

Males, 2006 All Ages Combined

Site/type	Total number of cancers	Incidence Rates per 100,000		
		Age-Standardized to 1970 <sup>a</sup>	to 2000 <sup>b</sup>	Crude rate <sup>c</sup>
All invasive	9913	486.27	585.69	581.00
Lymphoma				
Hodgkin	66	3.54	3.94	3.87
Non-Hodgkin	410	19.80	24.48	24.03
Oral cavity, pharynx	295	14.19	16.30	17.29
Esophagus	148	7.37	8.62	8.67
Stomach	213	10.00	12.66	12.48
Colon	646	30.87	39.24	37.86
Rectum	287	13.93	16.78	16.82
Liver	172	8.19	9.80	10.08
Gallbladder	55	2.70	3.43	3.22
Pancreas	256	12.37	15.26	15.00
Larynx	110	5.33	6.36	6.45
Lung	1303	63.63	78.73	76.37
Connective tissue	76	3.76	4.46	4.45
Melanoma, skin	541	26.18	31.32	31.71
Prostate	2944	148.65	170.71	172.55
Testis	98	5.07	5.86	5.74
Bladder	740	35.27	45.42	43.37
Kidney	369	17.77	21.36	21.63
Brain, CNS	128	6.43	7.27	7.50
Thyroid	124	6.22	7.04	7.27
Multiple myeloma	103	4.96	6.36	6.04
Leukemia	240	11.76	14.53	14.07
Kaposi sarcoma	13	.53	.73	.76
Unknown site	171	8.02	10.52	10.02
Chronic myeloprolif.	44	2.04	2.53	2.58
Myelodysplastic	98	4.39	6.22	5.74

<sup>a</sup>Using the age distribution of the total U.S. population in 1970 as the standard population in age-standardization.

<sup>b</sup>Using the age distribution of the total U.S. population in 2000 as the standard population.

<sup>c</sup>The number of cancers in males divided by the total male population of Connecticut in 2006 expressed as a rate per 100,000 males.

Note: "All invasive" includes cancer sites or types not shown separately in the Table.

**FEMALES**

**Numbers of Invasive Cancers and Age-Specific Incidence Rates (per 100,000)**

**Females, 2006: Age at Diagnosis 0-4 through 15-19 Years**

Site/type	Age 0-4		Age 5-9		Age 10-14		Age 15-19	
	18	18.17	11	10.17	16	13.54	13	10.63
All invasive	18	18.17	11	10.17	16	13.54	13	10.63
Lymphoma								
Hodgkin	0	.00	1	.92	3	2.54	0	.00
Non-Hodgkin	1	1.01	1	.92	2	1.69	1	.82
Oral cavity,								
Pharynx	1	1.01	0	.00	1	.85	0	.00
Esophagus	0	.00	0	.00	0	.00	0	.00
Stomach	0	.00	0	.00	0	.00	0	.00
Colon	0	.00	0	.00	1	.85	0	.00
Rectum	0	.00	0	.00	0	.00	0	.00
Liver	0	.00	0	.00	0	.00	0	.00
Gallbladder	0	.00	0	.00	1	.85	0	.00
Pancreas	0	.00	0	.00	0	.00	0	.00
Larynx	0	.00	0	.00	0	.00	0	.00
Lung	0	.00	0	.00	0	.00	0	.00
Connective tissue	2	2.02	0	.00	0	.00	2	1.64
Melanoma, skin	0	.00	0	.00	1	.85	1	.82
Breast	0	.00	0	.00	0	.00	0	.00
Uterine cervix	0	.00	0	.00	0	.00	0	.00
Uterine corpus	0	.00	0	.00	0	.00	0	.00
Ovary	0	.00	0	.00	0	.00	0	.00
Bladder	0	.00	0	.00	0	.00	0	.00
Kidney	0	.00	0	.00	0	.00	0	.00
Brain, CNS	3	3.03	5	4.62	2	1.69	2	1.64
Thyroid	0	.00	0	.00	0	.00	4	3.27
Multiple myeloma	0	.00	0	.00	0	.00	0	.00
Leukemia	7	7.07	3	2.77	2	1.69	1	.82
Kaposi sarcoma	0	.00	0	.00	0	.00	0	.00
Unknown site	1	.98	0	.00	1	.85	0	.00
Chronic myelo- proliferative	0	.00	0	.00	0	.00	0	.00
Myelodysplastic	0	.00	0	.00	0	.00	0	.00

CNS: Central nervous system.

All rates are per 100,000 (females) in the estimated population of Connecticut in 2006. Not all specific sites/types of cancer are shown separately, so that the sum of the numbers for all of the sites/types shown is less than the number for all invasive cancers combined. See Appendix for a list of codes used for the cancer sites or types shown.

**Numbers of Cancers, and Incidence Rates (per 100,000)**

**Females, 2006: Age at Diagnosis 20-24 through 35-39 Years**

Site/type	Age 20-24		Age 25-29		Age 30-34		Age 35-39	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate
All invasive	59	54.66	77	78.74	136	129.47	237	182.82
Lymphoma								
Hodgkin	9	8.34	10	10.23	4	3.81	4	3.09
Non-Hodgkin	6	5.56	1	1.02	4	3.81	8	6.17
Oral cavity,								
pharynx	0	.00	0	.00	3	2.86	5	3.86
Esophagus	0	.00	0	.00	0	.00	0	.00
Stomach	0	.00	2	2.05	1	.95	3	2.31
Colon	3	2.78	1	1.02	2	1.90	7	5.40
Rectum	1	.93	0	.00	0	.00	4	3.09
Liver	0	.00	0	.00	0	.00	1	.77
Gallbladder	0	.00	0	.00	0	.00	1	.77
Pancreas	0	.00	0	.00	0	.00	3	2.31
Larynx	0	.00	0	.00	0	.00	0	.00
Lung	1	.93	1	1.02	2	1.90	6	4.63
Connective tissue	1	.93	2	2.05	0	.00	4	3.09
Melanoma, skin	9	8.34	14	14.32	18	17.14	17	13.11
Breast	4	3.71	14	14.32	29	27.61	75	57.85
Uterine cervix	0	.00	6	6.14	10	9.52	10	7.71
Uterine corpus	0	.00	0	.00	4	3.81	11	8.49
Ovary	0	.00	1	1.02	5	4.76	1	.77
Bladder	0	.00	0	.00	0	.00	2	1.54
Kidney	0	.00	1	1.02	3	2.86	6	4.63
Brain, CNS	1	.93	3	3.07	5	4.76	3	2.31
Thyroid	15	13.90	17	17.38	38	36.17	41	31.63
Multiple myeloma	0	.00	0	.00	0	.00	0	.00
Leukemia	6	5.56	1	1.02	3	2.86	9	6.94
Kaposi sarcoma	0	.00	0	.00	0	.00	1	.77
Unknown site	0	.00	0	.00	0	.00	3	2.31
Chronic myelo- proliferative	0	.00	1	1.02	0	.00	3	2.31
Myelodysplastic	1	.93	0	.00	0	.00	1	.77

**Numbers of Cancers, and Incidence Rates (per 100,000)**

**Females, 2006: Age at Diagnosis 40-44 through 55-59 Years**

Site/type	Age 40-44		Age 45-49		Age 50-54		Age 55-59	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate
All invasive	448	302.63	737	491.97	849	647.19	908	775.52
Lymphoma								
Hodgkin	4	2.70	4	2.67	3	2.29	0	.00
Non-Hodgkin	4	2.70	23	15.35	31	23.63	37	31.60
Oral cavity, pharynx	3	2.03	11	7.34	10	7.62	13	11.10
Esophagus	0	.00	2	1.34	5	3.81	2	1.71
Stomach	3	2.03	6	4.01	10	7.62	7	5.98
Colon	19	12.83	20	13.35	40	30.49	41	35.02
Rectum	10	6.76	23	15.35	30	22.87	21	17.94
Liver	0	.00	4	2.67	6	4.57	6	5.12
Gallbladder	0	.00	0	.00	4	3.05	4	3.42
Pancreas	2	1.35	10	6.68	12	9.15	15	12.81
Larynx	2	1.35	4	2.67	4	3.05	3	2.56
Lung	21	14.19	40	26.70	82	62.51	104	88.83
Connective tissue	5	3.38	5	3.34	4	3.05	9	7.69
Melanoma, skin	37	24.99	46	30.71	38	28.97	45	38.43
Breast	202	136.45	325	216.95	338	257.66	291	248.54
Uterine cervix	14	9.46	14	9.35	6	4.57	13	11.10
Uterine corpus	17	11.48	32	21.36	63	48.02	93	79.43
Ovary	12	8.11	22	14.69	33	25.16	36	30.75
Bladder	3	2.03	8	5.34	19	14.48	19	16.23
Kidney	13	8.78	21	14.02	12	9.15	31	26.48
Brain, CNS	3	2.03	8	5.34	3	2.29	6	5.12
Thyroid	56	37.83	60	40.05	42	32.02	50	42.71
Multiple myeloma	2	1.35	5	3.34	6	4.57	13	11.10
Leukemia	6	4.05	10	6.68	13	9.91	12	10.25
Kaposi sarcoma	0	.00	0	.00	0	.00	0	.00
Unknown site	0	.00	8	5.34	11	8.39	13	11.10
Chronic myelo- proliferative	0	.00	3	2.00	2	1.52	2	1.71
Myelodysplastic	3	2.03	3	2.00	3	2.29	2	1.71

Numbers of Cancers, and Incidence Rates (per 100,000)

Females, 2006: Age at Diagnosis 60-64 through 75-79 Years

Site/type	Age 60-64		Age 65-69		Age 70-74		Age 75-79	
	Number	Rate	Number	Rate	Number	Rate	Number	Rate
All invasive	974	1107.85	969	1488.57	1016	1781.27	1154	2126.68
Lymphoma								
Hodgkin	1	1.14	4	6.14	1	1.75	8	14.74
Non-Hodgkin	38	43.22	27	41.48	47	82.40	52	95.83
Oral cavity,								
pharynx	11	12.51	11	16.90	14	24.55	17	31.33
Esophagus	7	7.96	7	10.75	3	5.26	8	14.74
Stomach	7	7.96	11	16.90	14	24.55	14	25.80
Colon	45	51.18	72	110.61	75	131.49	110	202.72
Rectum	28	31.85	37	56.84	24	42.08	30	55.29
Liver	5	5.69	5	7.68	5	8.77	8	14.74
Gallbladder	6	6.82	4	6.14	6	10.52	11	20.27
Pancreas	16	18.20	19	29.19	35	61.36	42	77.40
Larynx	5	5.69	7	10.75	6	10.52	4	7.37
Lung	154	175.16	169	259.62	206	361.16	214	394.38
Connective tissue	8	9.10	7	10.75	12	21.04	9	16.59
Melanoma, skin	26	29.57	31	47.62	35	61.36	27	49.76
Breast	313	356.01	286	439.35	252	441.81	274	504.95
Uterine cervix	13	14.79	15	23.04	8	14.03	7	12.90
Uterine corpus	89	101.23	71	109.07	64	112.21	64	117.94
Ovary	27	30.71	31	47.62	35	61.36	31	57.13
Bladder	36	40.95	27	41.48	38	66.62	55	101.36
Kidney	24	27.30	25	38.40	28	49.09	34	62.66
Brain, CNS	16	18.20	9	13.83	9	15.78	14	25.80
Thyroid	23	26.16	36	55.30	14	24.55	14	25.80
Multiple myeloma	6	6.82	4	6.14	17	29.80	18	33.17
Leukemia	18	20.47	15	23.04	13	22.79	18	33.17
Kaposi sarcoma	0	.00	0	.00	0	.00	0	.00
Unknown site	21	23.89	16	24.58	22	38.57	27	49.76
Chronic myelo- proliferative	3	3.41	3	4.61	1	1.75	9	16.59
Myelodysplastic	5	5.69	5	7.68	10	17.53	10	18.43

Numbers of Cancers, and Incidence Rates (per 100,000)

Females, 2006: Age at Diagnosis 80-84 through 85+ Years

Site/type	Age 80-84		Age 85+	
	Number	Rate	Number	Rate
All invasive	1079	2286.31	1117	2106.87
Lymphoma				
Hodgkin	4	8.48	4	7.54
Non-Hodgkin	46	97.47	50	94.31
Oral cavity,				
pharynx	18	38.14	10	18.86
Esophagus	9	19.07	9	16.98
Stomach	19	40.26	25	47.15
Colon	139	294.53	166	313.11
Rectum	32	67.81	50	94.31
Liver	8	16.95	16	30.18
Gallbladder	11	23.31	19	35.84
Pancreas	50	105.95	44	82.99
Larynx	1	2.12	2	3.77
Lung	200	423.78	135	254.64
Connective tissue	11	23.31	7	13.20
Melanoma, skin	26	55.09	34	64.13
Breast	225	476.76	192	362.15
Uterine cervix	4	8.48	3	5.66
Uterine corpus	28	59.33	33	62.24
Ovary	25	52.97	34	64.13
Bladder	53	112.30	50	94.31
Kidney	19	40.26	26	49.04
Brain, CNS	14	29.66	10	18.86
Thyroid	11	23.31	9	16.98
Multiple myeloma	9	19.07	18	33.95
Leukemia	28	59.33	29	54.70
Kaposi sarcoma	0	.00	0	.00
Unknown site	31	65.69	67	126.37
Chronic myelo-				
Proliferative	6	12.71	4	7.54
Myelodysplastic	21	44.50	22	41.50

**Numbers of Cancers, and Incidence Rates (per 100,000)**

**Females, 2006: All Ages Combined**

Site/type	Total number of cancers	Incidence Rates per 100,000		
		Age-Standardized to 1970 <sup>a</sup>	to 2000 <sup>b</sup>	Crude Rate <sup>c</sup>
All invasive	9818	379.99	456.34	545.86
Lymphoma				
Hodgkin	64	3.30	3.52	3.56
Non-Hodgkin's	379	14.51	17.37	21.07
Oral cavity, pharynx	128	4.99	6.02	7.12
Esophagus	52	1.84	2.26	2.89
Stomach	122	4.25	5.42	6.78
Colon	741	24.68	32.04	41.20
Rectum	290	10.63	12.96	16.12
Liver	64	2.13	2.72	3.56
Gallbladder	67	2.16	2.81	3.73
Pancreas	248	8.42	10.89	13.79
Larynx	38	1.62	1.84	2.11
Lung	1335	50.83	61.28	74.22
Connective tissue	88	3.64	4.24	4.89
Melanoma, skin	405	16.85	19.87	22.52
Breast	2820	112.85	133.50	156.79
Uterine cervix	123	5.45	6.37	6.84
Uterine corpus	569	23.56	26.74	31.64
Ovary	293	11.35	13.51	16.29
Bladder	310	10.93	13.70	17.24
Kidney	243	9.43	11.34	13.51
Brain, CNS	116	5.16	5.71	6.45
Thyroid	430	19.42	22.54	23.91
Multiple myeloma	98	3.46	4.36	5.45
Leukemia	194	7.85	9.11	10.79
Kaposi sarcoma	1	.04	.06	.06
Unknown site	220	7.04	9.17	12.23
Chronic myeloprolif- erative	37	1.34	1.71	2.06
Myelodysplastic	86	2.70	3.63	4.78

<sup>a</sup>Using the age distribution of the total U.S. population in 1970 as the standard.

<sup>b</sup>Using the age distribution of the total U.S. population in 2000 as the standard.

<sup>c</sup>Number of cancers divided by the total female population of Connecticut in 2006, expressed as a rate per 100,000 females.

Note: "All invasive" includes other sites or types not shown separately in the table.



## APPENDIX

### A. International Classification of Diseases for Oncology, Version 3 (ICD-O-3) Codes

#### 1. Lymphomas

HODGKIN'S: Morphology codes 9650-9667  
NON-HODGKIN'S: Morphology codes 9590-9591,  
9670-9729; 9823, 9827 (except for site codes 420, 421, 424)

#### 2. Excluding Lymphomas

"C" is part of the ICD-O site code

ORAL CAVITY, PHARYNX: C 00.0-14.8.  
ESOPHAGUS: C 15.0-15.9.  
STOMACH: C 16.0-16.9.  
COLON: C 18.0-18.9.  
RECTUM, ANUS: C 19.9, 20.9-21.8.  
LIVER: C 22.0-22.1.  
GALLBLADDER: C 23.9-24.9 (includes extrahepatic bile ducts)  
PANCREAS: C 25.0-25.9.  
LARYNX: C 32.0-32.9.  
TRACHEA, BRONCHUS, LUNG: C 33.9-34.9.  
CONNECTIVE TISSUE: C 49.0-49.9.  
MELANOMA OF SKIN: C 44.0-44.9, Morphology 8720-8790.  
PROSTATE: C 61.9.  
FEMALE BREAST: Sex female and C 50.0-50.9.  
TESTIS: C 62.0-62.9.  
CERVIX UTERUS: C 53.0-53.9.  
UTERINE CORPUS, AND UTERUS NOT OTHERWISE  
SPECIFIED: C 54.0-54.9, 55.9.  
OVARY, ADJACENT STRUCTURES: C 56.9-57.8.  
BLADDER: C 67.0-67.9.  
KIDNEY, RENAL PELVIS, URETER: C 64.9-66.9.  
BRAIN, CENTRAL NERVOUS SYSTEM (CNS):  
CEREBRAL MENINGES, CRANIAL NERVES:  
C 70.0-71.9, 72.2-72.5.  
THYROID: C 73.9.  
MULTIPLE MYELOMA: Morphology 9731-9732.  
LEUKEMIA: Morphology 9800-9822;9826;9832-9948;9823 and  
9827 (site codes 420, 421, 424)  
KAPOSI'S SARCOMA: Morphology 9140.  
UNKNOWN SITE: C 76.0-76.8, 80.0-80.9 (ill-defined or unknown  
primary site).  
CHRONIC MYELOPROLIFERATIVE DISORDERS (Site 42.1): Morphology  
9950-9964.  
MYELODYSPLASTIC SYNDROMES (Site 42.1): Morphology 9980-9989.

Reference: Fritz A, Percy C, Jack A et al. (editors) *International  
Classification of Diseases for Oncology. Third Edition*. Geneva,  
Switzerland, World Health Organization, 2000.

Note: These groupings for cancer site/type were selected for  
consistency with past reports from the Connecticut Tumor Registry.

## Appendix

### B. Connecticut Population Estimates by Age and Sex: July 1, 2006

From Annual Population Estimates  
U.S. Census Bureau. American FactFinder.  
[www.census.gov](http://www.census.gov)

Age (years)	Male	Female
0-4	103,776	99,055
5-9	113,266	108,111
10-14	123,543	118,150
15-19	127,815	122,256
20-24	114,136	107,942
25-29	100,678	97,793
30-34	104,663	105,047
35-39	126,026	129,636
40-44	142,119	148,035
45-49	143,417	149,806
50-54	125,646	131,182
55-59	107,486	117,082
60-64	79,782	87,918
65-69	57,065	65,096
70-74	45,694	57,038
75-79	39,584	54,263
80-84	28,114	47,194
85 and over	23,378	53,017
Total	1,706,188	1,798,621